Boston Scientific receives CE Tag approval for TAXUS Component Paclitaxel-Eluting Coronary Stent System Angiotech Pharmaceuticals, Inc. today announced that its corporate partner, Boston Scientific Company , provides received CE Mark approval because of its TAXUS Component Paclitaxel-Eluting Coronary Stent Program, Boston Scientific’s third-era drug-eluting stent technology here mebeverine.org . This approval carries a particular indication for the treating diabetics. The TAXUS Component Stent System includes a platinum chromium alloy with a forward thinking stent design and a sophisticated catheter delivery program.